Latin American Pharma Market Witnesses Increasing Investment, with Companies Looking to Further Operations in the Region
Approximately $12.7 billion has been invested in Latin America’s (LATAM’s) pharmaceutical market through mergers and acquisitions (M&As) in recent years, and with untapped potential identified in countries across the region, companies are expected to seize upon further opportunities to drive future growth, says a new report from research and consulting firm GlobalData.
According to the company’s latest report*, the number of M&As completed in the region increased by a massive 214% between 2008 and 2012, and accounted for the majority (approximately 70%) of the region’s total deals during this period, followed by licensing agreements. Combined, these two categories remain one of the most popular sources of investment in the LATAM sector.
Aparna Krishnan, GlobalData’s Analyst covering Healthcare Industry Dynamics, says: “M&As in this region have mainly consisted of global pharma firms acquiring local companies, which represents a shift towards emerging markets that will help boost revenue growth.
“The largest deal that took place between 2008 and 2012 involved UnitedHealth’s acquisition of Brazil’s Amil Particapacoes in 2012, which cost the US-based firm a massive $4.9 billion.”
In terms of therapeutic areas, the LATAM region’s oncology sector witnessed the most significant number of deals between 2008 and 2012, which reached approximately 120 in total. This was followed by areas related to the central nervous system and immunology.
According to GlobalData, the high level of investment activity in oncology comes in response to recent studies, which depict a rise in incidence levels and mortality rates that LATAM’s current health systems are unable to handle adequately. As a result, the region’s governments have increased investments in disease surveillance and embarked on preventive campaigns.
While such untapped potential currently exists in LATAM’s pharmaceutical industry, a number of barriers will first need to be overcome by companies looking to seize upon the opportunities.
Krishnan says: “In addition to unstable political conditions standing in the way of markets such as Cuba and Venezuela, various sectoral challenges, including intellectual property rights and the intense impact of a high-volume, small margin-based generics market, are also proving a hindrance.
“Nevertheless, thanks to low-cost drug manufacturing and clinical trial opportunities, pharma firms will continue to benefit from having a presence in the region,” the analyst concludes.
*PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008–2012
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance